Sexual dysfunction in women
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
sexual interest/arousal disorder
psychological therapy
Use of each of the psychological treatments (psychoeducation, cognitive behavioral therapy [CBT], sex therapy, psychotherapy, mindfulness, and mindfulness-based cognitive therapy [MBCT]) can be helpful for women with sexual interest/arousal disorder.
Psychoeducation is given to all women treated for sexual concerns.
Psychoeducation that incorporates mindfulness has also been found helpful for women with sexual interest/arousal disorder.[125]Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med. 2008 Jul;5(7):1646-59. http://www.ncbi.nlm.nih.gov/pubmed/18507718?tool=bestpractice.com [126]Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther. 2014 Jun;57:43-54. http://www.ncbi.nlm.nih.gov/pubmed/24814472?tool=bestpractice.com
MBCT, in addition to other mindfulness practices, identifies maladaptive and exaggerated thoughts, but rather than changed, as in CBT, they are simply viewed as "mental events," "what the brain does," and not necessarily true. Encouragement is given to just let them exist for now without following or believing them. Benefit for women with sexual interest/arousal disorder as compared to detailed assessment and wait list has been shown.[126]Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther. 2014 Jun;57:43-54. http://www.ncbi.nlm.nih.gov/pubmed/24814472?tool=bestpractice.com [127]Mize SJS. A review of mindfulness-based sex therapy interventions for sexual desire and arousal difficulties: from research to practice. Curr Sex Health Rep. 2015;7:89-97.[144]Hucker A, McCabe MP. An online, mindfulness-based, cognitive-behavioral therapy for female sexual difficulties: impact on relationship functioning. J Sex Marital Ther. 2014;40(6):561-76. http://www.ncbi.nlm.nih.gov/pubmed/24308322?tool=bestpractice.com
estrogen or dehydroepiandrosterone
Treatment recommended for SOME patients in selected patient group
Vaginal estrogen: indicated if loss of genital arousal is due to vulvovaginal atrophy. Any vaginal formulation is appropriate (e.g., estradiol vaginal tablet, vaginal ring, or vaginal cream).[146]Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017 Dec;92(12):1842-9. https://www.mayoclinicproceedings.org/article/S0025-6196(17)30639-0/fulltext http://www.ncbi.nlm.nih.gov/pubmed/29202940?tool=bestpractice.com However, it should be noted that high-dose estradiol cream (containing estradiol 100 micrograms/g or 0.01%) should be limited to a single treatment period of up to 4 weeks due to the risk of adverse effects usually associated with systemic (oral or transdermal) hormone replacement therapy, and other vaginal estrogen formulations may be preferred.[147]European Medicines Agency. Four-week limit for use of high-strength estradiol creams. 10 April 2019 [internet publication]. https://www.ema.europa.eu/en/news/four-week-limit-use-high-strength-estradiol-creams There is no approval for use of vaginal estrogen in women with previous estrogen-dependent breast cancer; each woman must be assessed individually.[30]Basson R, Bronner G. Management and rehabilitation of neurologic patients with sexual dysfunction. In: Vodusek DB, Boller F, eds. Handbook of clinical neurology. Vol. 130. Waltham, MA: Elsevier; 2015:415-34. The American College of Obstetrics and Gynecologists advise that in these patients it should be reserved for those who are unresponsive to nonhormonal remedies.[148]American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Farrell R. ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016 Mar;127(3):e93-6. http://www.ncbi.nlm.nih.gov/pubmed/26901334?tool=bestpractice.com
Systemic estrogen: only indicated if loss of genital congestion is identified to be due to vulvovaginal atrophy and systemic estrogen is preferred because of other menopausal health considerations. Meta-analysis suggests estrogens alone or in combination with progestogens can allow a small to moderate improvement in sexual function, but mostly in pain, but not in unselected postmenopausal women.[149]Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013 Jun 5;(6):CD009672. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009672.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/23737033?tool=bestpractice.com
Vaginal dehydroepiandrosterone (DHEA): preliminary evidence suggests vaginal DHEA benefits both atrophy (dryness and dyspareunia) and sexual response (orgasm intensity and desire/motivation).[46]Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009 Sep-Oct;16(5):923-31. http://www.ncbi.nlm.nih.gov/pubmed/19424093?tool=bestpractice.com It is approved by the Food and Drug Administration for dyspareunia related to menopause. Randomized controlled trials also confirm enhanced genital sexual sensitivity as reflected by ease and intensity of orgasm, and increased desire in postmenopausal women.[150]Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015 Dec;12(12):2401-12. http://www.ncbi.nlm.nih.gov/pubmed/26597311?tool=bestpractice.com
Dose depends on type of estrogen and formulation; consult specialist for guidance on dose.
female orgasmic disorder (FOD)
psychological therapy
Psychological methods are the mainstay of therapy in lifelong FOD.
Cognitive behavioral therapy (CBT) and behavioral techniques have been found across studies to be highly effective for women with lifelong FOD.[35]Heiman JR. Orgasmic disorders in women. In: Leiblum SR, ed. Principles and practice of sex therapy. 4th ed. New York, NY: Guilford Press; 2007:66-8. For all women with FOD, education on anatomy and physiology may be given, along with normalising the absence of coital orgasms, while simultaneously attending to affect and irrational thoughts.
First-line behavioral treatments are guided/directed self-stimulation and coital alignment technique (CAT).
Guided/directed self-stimulation: of the various behavioral techniques, directed self-stimulation is used most frequently and has the most empiric support for lifelong FOD. It involves education and information followed by body awareness exercises designed to enhance women's awareness of their genitals and to challenge any negative or distorted thoughts that might emerge. The exercises progressively increase in intensity, including using a hand-held mirror to enhance sensory experience, until the woman learns to reach orgasm on her own. She is then guided on how to transfer this new knowledge to a partner. Success rates for directed self-stimulation are high (80% to 90%), but the success rate for secondary FOD is lower (10% to 75%).[171]LoPiccolo J, Stock WE. Treatment of sexual dysfunction. J Consult Clin Psychol. 1986 Apr;54(2):158-67. http://www.ncbi.nlm.nih.gov/pubmed/3700802?tool=bestpractice.com [172]Fichten CS, Libman E, Brender W. Methodological issues in the study of sex therapy: effective components in the treatment of secondary orgasmic dysfunction. J Sex Marital Ther. 1986 Spring;12(1):22-34. http://www.ncbi.nlm.nih.gov/pubmed/3959099?tool=bestpractice.com
CAT: CAT is a behavioral technique in which the male partner lies on top of and slightly more forward on his partner so that there is direct clitoral pressure during intercourse. One study that directly compared CAT with directed self-stimulation for women with secondary FOD found that CAT produced a significantly better response (37% of women in CAT group gained >50% improvement versus 18% in the directed self-stimulation group).[173]Hurlbert DF, Apt CV. The coital alignment technique and directed masturbation: a comparative study on female orgasm. J Sex Marital Ther. 1995 Spring;21(1):21-9. http://www.ncbi.nlm.nih.gov/pubmed/7608994?tool=bestpractice.com
Mindfulness: this involves learning to be present in the moment, and not react to potentially negative feelings or thoughts, but simply observe them and return to the sexual sensations. Although scientific study of the benefits is only just beginning, clinical experience supports the use of this meditative skill for FOD.
Mindfulness-based cognitive therapy: In addition to mindfulness practices, maladaptive and exaggerated thoughts are identified, but rather than changed, as in CBT, they are simply viewed as "mental events," "what the brain does," and not necessarily true. Encouragement is given to just let them exist for now without following or believing them. Benefit for women with sexual interest/arousal disorder as compared to detailed assessment and wait list has been shown.[126]Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther. 2014 Jun;57:43-54. http://www.ncbi.nlm.nih.gov/pubmed/24814472?tool=bestpractice.com
Psychological techniques used in lifelong FOD can also be effective in acquired cases. Interpersonal issues such as trust may need addressing. Personal psychological issues related to the woman's past may have surfaced (e.g., onset of problem coincident with giving birth) to lead to new onset orgasmic disorder.
vibrostimulation
Treatment recommended for SOME patients in selected patient group
Can increase the stimulus by providing more prolonged direct stimulation to clitoral tissue, including the clitoral bulbs deep to the superficial perineal muscles and around the urethra in the anterior vaginal wall (the so-called G spot). This can be recommended in addition to skills to stay focused such as mindfulness training, but outcomes have not been published.
When there is associated neurologic disease leading to acquired FOD, different and stronger means of sexual stimuli are encouraged (e.g., vibrostimulation, the use of fantasy, and stimulation of other parts of the body when there is loss of genital sensation). Treatment strategies vary depending on type of neurologic condition and sexual symptoms.[73]Hentzen C, Musco S, Amarenco G, et al. Approach and management to patients with neurological disorders reporting sexual dysfunction. Lancet Neurol. 2022 Jun;21(6):551-62. http://www.ncbi.nlm.nih.gov/pubmed/35405093?tool=bestpractice.com Women with spinal cord injury can have orgasms from vibrostimulation to the cervix.[73]Hentzen C, Musco S, Amarenco G, et al. Approach and management to patients with neurological disorders reporting sexual dysfunction. Lancet Neurol. 2022 Jun;21(6):551-62. http://www.ncbi.nlm.nih.gov/pubmed/35405093?tool=bestpractice.com [74]Rees P, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 2007 Feb 10;369(9560):512-25. http://www.ncbi.nlm.nih.gov/pubmed/17292771?tool=bestpractice.com
substance/medication-induced sexual dysfunction
psychological therapy
Up to 70% of women prescribed antidepressants, if asked directly, will admit to medication-associated dysfunction.[174]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 suppl 3:10-21. http://www.ncbi.nlm.nih.gov/pubmed/11229449?tool=bestpractice.com A major limitation in this research is that both antidepressants and depression are associated with sexual dysfunction, so it is difficult to determine precise etiology.
General psychological techniques are applicable to women with antidepressant-induced FOD. Psychoeducation on the mechanisms by which iatrogenic FOD can affect a woman's sense of self, mood, and relationship is given. Mindfulness techniques that teach women to attune to genital arousal, and psychological techniques that encourage women to challenge irrational thoughts about themselves as being "dysfunctional," have shown to be helpful clinically.
Mindfulness-based cognitive therapy, in addition to mindfulness practices, identifies maladaptive and exaggerated thoughts, but rather than changed, as in cognitive behavioral therapy, they are simply viewed as "mental events," "what the brain does," and not necessarily true. Encouragement is given to just let them exist for now without following or believing them. Benefit for women with sexual interest/arousal disorder as compared to detailed assessment and wait list has been shown.[126]Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther. 2014 Jun;57:43-54. http://www.ncbi.nlm.nih.gov/pubmed/24814472?tool=bestpractice.com
review antidepressant therapy
Treatment recommended for SOME patients in selected patient group
For sexual dysfunction associated with antidepressant use, consider lowering the antidepressant dose; switching to an alternative antidepressant that is associated with a lower risk of sexual dysfunction (e.g., vilazodone, vortioxetine, bupropion); using an add-on treatment (e.g., bupropion, buspirone); or replacing medication with another mode of therapy if safe to do so.[153]Montejo AL, Prieto N, de Alarcón R, et al. Management strategies for antidepressant-related sexual dysfunction: A clinical approach. J Clin Med. 2019 Oct 7;8(10):1640. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832699 http://www.ncbi.nlm.nih.gov/pubmed/31591339?tool=bestpractice.com [154]Winter J, Curtis K, Hu B, et al. Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management. Expert Opin Drug Saf. 2022 Jul;21(7):913-30. http://www.ncbi.nlm.nih.gov/pubmed/35255754?tool=bestpractice.com
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer